CD14^(+)CD16^(-)HLA^(-)DR^(+)与PD-1单抗治疗非小细胞肺癌的疗效及预后的关系研究

Correlation between CD14^(+)CD16^(-)HLA^(-)DR^(+)levels with the efficacy and prognosis of PD-1 monoclonal antibody in non-small cell lung cancer

目的分析CD14^(+)CD16^(-)HLA^(-)DR^(+)与程序性死亡受体-1(PD-1)单抗治疗非小细胞肺癌的临床疗效和患者预后的关系,为临床应用提供依据。方法选择该院2018年6月至2019年4月收治的60例非小细胞肺癌患者作为研究对象;采用PD-1单抗进行干预治疗;采用RECIST Version1.1对患者的临床疗效进行评估;对患者进行长期随访追踪,记录患者生存率。结果CD14^(+)CD16^(-)HLA^(-)DR^(+)组患者采用PD-1单抗治疗后的疗效明显优于CD14^(+)CD16^(-)HLA^(-)DR^(-/low)组,差异有统计学意义(P<0.05);CD14^(+)CD16^(-)HLA^(-)DR^(+)组患者生存率明显优于CD14^(+)CD16^(-)HLA^(-)DR^(-/low)组患者,差异有统计学意义(P<0.05);CD14^(+)CD16^(-)HLA^(-)DR^(+)是非小细胞肺癌采用PD-1单抗治疗后的临床疗效及预后的独立影响因素(P<0.05)。结论非小细胞肺癌患者采用PD-1单抗治疗后具有较好的临床疗效,CD14^(+)CD16^(-)HLA^(-)DR^(+)患者的临床疗效以及预后生存期明显升高。

Objective To analyze the correlation between the CD14^(+)CD16^(-)HLA^(-)DR^(+)with clinical efficacy of programmed death receptor-1(PD-1)monoclonal antibody drug treatment and the prognosis of patient with non-small cell lung cancer,so as to provide data support for clinical application.Methods From June 2018 to April 2019,60 patients with non-small cell lung cancer were selected as subjects;PD-1 monoclonal antibody were used for intervention treatment.The clinical efficacy of the patients was evaluated according to RECIST Version1.1.The patients were followed up for a long time and the survival rate was recorded.Results The clinical therapeutic effect of patients in CD14^(+)CD16^(-)HLA^(-)DR^(+)group was significantly better than that in CD14^(+)CD16^(-)HLA^(-)DR^(-/low)group,and the difference was statistically significant(P<0.05).Survival rate of CD14^(+)CD16^(-)HLA^(-)DR^(+)group was significant higher than that of CD14^(+)CD16^(-)HLA^(-)DR^(-/low)group(P<0.05).CD14^(+)CD16^(-)HLA^(-)DR^(+)was the influenced factor of clinical effect and prognosis quality after treatment with PD-1 monoclonal antibody in patients with non-small cell lung cancer(P<0.05).Conclusion Patients with non-small cell lung cancer have higher clinical efficacy after treatment with PD-1 monoclonal antibody.The clinical efficacy of CD14^(+)CD16^(-)HLA^(-)DR^(+)treatment and the prognosis of patients are significantly increased.